Latest News

MMS Holdigns Joins DTRA as A Founding Member to Accelerate The Adoption of Patient- Focused

CANTON, Mich. (January 29, 2021) – MMS Holdings – an award-winning, data-focused CRO – joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched on December 10th, 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices, and new technologies in decentralized clinical research.

“As a specialized data services and technologies provider, MMS will help guide the life sciences industry into an exciting future where decentralized trials and research help the world find treatments and cures at a more rapid pace,” said Eric Harvey, Director of Biostatistics and Data Science, MMS. “We believe that innovation and growth has a place in every part of our industry, and the proliferation of decentralized clinical trials is set to become one of the biggest changes that we’ve seen in industry in the past decade.”

“We are extremely gratified to welcome MMS to the Decentralized Trials & Research Alliance,” said Amir Kalali, MD, founder of several collaborative life science communities, and co-convenor of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by MMS’ commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”

Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge.  COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, MMS is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials.  “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”

MMS joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. MMS urges other organizations interested in taking part to visit DTRA.org.

ABOUT DTRA

The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.

ABOUT MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.

For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

For further information please contact:
Media Contacts

For DTRA:
Glenn Silver
Lazar – Finn Partners
glenn.silver@finnpartners.com
646 871 8485


For MMS:

Prasad Babu
media@mmsholdings.com

For Non-media Inquiries:

DTRA Secretariat
secretariat@dtra.org
619-209-7371

Suggested For You

news

July 15th, 2021

Health Data Research UK Selects MMS as Data Services Partner for the International COVID-19 Data Alliance

news

March 4th, 2020

MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals

news

January 25th, 2019

BREAKING NEWS: MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective

news

November 2nd, 2018

Chris Hurley Asked to Renew Three-Year Term as Americas Director of Leading Data Sciences Organization PhUSE

news

April 4th, 2024

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

news

August 16th, 2022

Together Trial with EDC Database Designed by MMS Wins Trial of the Year

news

June 7th, 2022

MMS Holdings Announces Partnership with Medidata to Provide Medidata’s Advanced Rave EDC and Decentralized Clinical Trial Solutions to Sponsors

news

May 24th, 2022

MMS Holdings Selects THREAD as Partner of Choice to Deliver Decentralized Clinical Trials

news

November 19th, 2021

Former Astellas VP of Biostatistics Joins MMS as Principal Advisor of Biostatistics

news

July 28th, 2021

Data CRO Expands its Virtual Learning Portfolio

news

May 19th, 2020

University of Michigan School of Information Invites MMS Holdings Executive Kelly J. Hill to Join External Advisory Board

news

November 20th, 2019

MMS Holdings Doubles Growth In South Africa Region